MGI Tech Celebrates 10 Years of Innovation, Empowering 3,560 Users Across Six Continents
SHENZHEN, China, April 13, 2026 /PRNewswire/ -- MGI Tech Co., Ltd. (MGI), a company dedicated to developing core tools and technologies that drive innovation in life sciences, celebrates its 10th anniversary, a decade marked by breakthroughs that have helped transform genomics into a scalable, data-driven and accessible engine of discovery. Since its founding in 2016, MGI has tackled the...
Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain
BEIJING, April 13, 2026 /PRNewswire/ -- On April 10, 2026, Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with AbbVie (NYSE: ABBV), a global biopharmaceutical company. Under the agreement, Haisco grants AbbVie the exclusive rights to develop, manufacture, and commercialize novel medicines for the treatment of pain globally, excluding mainland...
AnBogen Therapeutics to Present Dual Breakthroughs for Imofinostat (ABT-301) at AACR 2026: Addressing Immunotherapy Barriers in CRC and Chemo-resistance in Pancreatic Cancer
TAIPEI, April 13, 2026 /PRNewswire/ -- AnBogen Therapeutics, a clinical-stage biotechnology company focused on precision oncology, today announced that two key research abstracts regarding its lead compound, Imofinostat (ABT-301), have been selected for poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The data demonstrate ABT-301's superior performance in enhancing immunotherapy for colorectal cancer (CRC)...
Telix and Regeneron Announce Strategic Radiopharma Collaboration
Telix and Regeneron to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model. Collaboration combines Telix's expertise in radiopharmaceutical development and manufacturing with Regeneron's leading antibody discovery/development platforms and oncology experience. Telix to receive US$40 million upfront for four initial programs with optionality on a per...
Sinocare Showcases Digital Innovation at the 93rd CMEF, Advancing Global Chronic Disease Management
SHANGHAI, April 11, 2026 /PRNewswire/ -- At the 93rd China International Medical Equipment Fair (CMEF), Sinocare presented its latest advancements under the theme "Leading Digital Healthcare For Global Health." Bringing together cutting-edge technologies, integrated solutions, and strategic partnerships, the company demonstrated its ambition to redefine chronic disease management on a global scale....
Helping Pets Breathe Easier with VARON Oxygen Therapy Bundles
NEW YORK, April 11, 2026 /PRNewswire/ -- When every breath becomes a struggle for a pet, timely pet oxygen concentrator can make a meaningful difference. Until recently, this level of care was largely limited to veterinary clinics. VARON now brings veterinary-inspired respiratory support into the home with its expanded line of oxygen concentrator therapy bundles. Designed for pets in...
SINGAPORE STRENGTHENS SARCOMA CARE THROUGH COORDINATED, MULTIDISCIPLINARY APPROACH
NCIS leads multi-institutional effort to develop expert multidisciplinary guidance to improve sarcoma diagnosis, referrals and outcomes SINGAPORE, April 11, 2026 /PRNewswire/ -- Singapore is strengthening its approach to sarcoma care, a rare group of bone and soft tissue cancers that disproportionately affect adolescents and young adults, through closer coordination across specialties and...
Miracell Receives FDA 510(k) Clearance for SMART M-CELL PRP Concentration System and SMART M-CELL Bone Marrow Concentration System
Blood- and bone marrow-based efficient growth factors extraction system demonstrates substantial equivalence and high cell viability SEOUL, South Korea, April 10, 2026 /PRNewswire/ -- Miracell, a leading stem cell technology company, announced that it has obtained U.S. FDA 510(k) clearance for its stem cell extraction system, SMART M-CELL, along with its dedicated kits, the BSC Blood Kit and BMSC...
Vivatides Therapeutics Announces Oversubscribed $54 Million Series A Financing to Accelerate Extrahepatic RNA Therapeutics Development
Advancing next-generation RNA therapeutics beyond the liver through breakthrough delivery technologies SUZHOU, China and BOSTON, April 10, 2026 /PRNewswire/ -- Vivatides Therapeutics, a global biotechnology company focused on developing extrahepatic RNA-targeting therapeutics, announced the successful closing of an oversubscribed $54 million Series A financing. The round was co-led by Qiming Venture Partners and a leading industry fund,...
Ceva Animal Health appoints Sébastien Huron as Deputy Chief Executive Officer
LIBOURNE, France, April 10, 2026 /PRNewswire/ -- Ceva Animal Health, the world's fifth largest animal health company, majority-owned by its management team, today announces the appointment of Sébastien Huron as Deputy Chief Executive Officer, effective immediately. This move forms part of a broader governance evolution, following Marc Prikazsky's decision to appoint a...
